Efficacy and safety of vancomycin compared with those of alternative treatments for methicillin‐resistant Staphylococcus aureus infections: An umbrella review
Journal of Evidence-Based Medicine · 2024-12 · 17 (4) · 729-739
DOI: 10.1111/jebm.12644 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Evidence-Based Medicine, online erschienen am 30.09.2024. Verfasst von Sujata Purja und 4 weiteren Autor:innen. Beteiligte Einrichtung: Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang Un…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Vancomycin. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and ICT, MICT, Ministry of Education, Ministry of Food and Drug Safety of South Korea in 2022-2025.
Abstract (Originalsprache)
Objective
To summarize the evidence on the efficacy and safety of vancomycin compared with those of alternative treatments in adult patients with methicillin‐resistant Staphylococcus aureus (MRSA) infection.
Methods
PubMed, Embase, and Web of Science were searched up to December 15, 2023, for systematic reviews and meta‐analyses comparing vancomycin with alternative MRSA treatments. Primary outcomes included clinical cure and microbiological eradication rates. Organ‐specific safety outcomes were assessed. Summary estimates were recalculated using a random‐effects model. Evidence was graded using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) tool. This study was registered in PROSPERO (CRD42022340359).
Results
This umbrella review included 19 studies and 71 meta‐analyses (46 efficacy and 25 safety) comparing vancomycin with 10 alternative treatments across different MRSA infection types and populations. GRADE assessment showed that 29.58% of the meta‐analyses were of high quality. Linezolid and daptomycin showed higher efficacy in MRSA‐induced skin and soft tissue infections and pneumonia (moderate evidence quality) and bacteremia (very low evidence quality), respectively, compared with that of vancomycin. Cephalosporins had a higher risk of nausea, whereas linezolid had a higher risk of nausea, diarrhea, and thrombocytopenia than that of vancomycin. Vancomycin posed a higher risk of rash, pruritus, red man syndrome, and nephrotoxicity than that of alternatives.
Conclusions
The quality of evidence supporting the higher efficacy of alternative treatment over vancomycin for MRSA infection was not high. Given varying safety profiles and advancements in therapeutic monitoring, careful consideration of patient‐specific factors and pharmacokinetics is crucial when selecting treatment alternatives to vancomycin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
- Central Research Center of Epigenome-Based Platform and Its Application for Drug Development, College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- College of Pharmacy, University of Health Science and Pharmacy in St. Louis, Missouri, USA.
- The Graduate School for Pharmaceutical Industry Management, College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
- Regulatory Science Policy, Pharmaceutical Regulatory Sciences, Chung-Ang University, Seoul, Republic of Korea.
ORCID-Profile: Sujata Purja, Yomna Elghanam, Eunyoung Kim
Förderung
- Ministry of Science and ICT, MICT
- Ministry of Education
- Ministry of Food and Drug Safety of South Korea in 2022-2025
Zitieren
APA
Purja, S., Kim, M., Elghanam, Y., Shim, H. J., & Kim, E. (2024). Efficacy and safety of vancomycin compared with those of alternative treatments for methicillin‐resistant Staphylococcus aureus infections: An umbrella review. Journal of Evidence-Based Medicine, 17(4), 729-739. https://doi.org/10.1111/jebm.12644
Vancouver
Purja S, Kim M, Elghanam Y, Shim HJ, Kim E. Efficacy and safety of vancomycin compared with those of alternative treatments for methicillin‐resistant Staphylococcus aureus infections: An umbrella review. Journal of Evidence-Based Medicine. 2024;17(4):729-739. doi:10.1111/jebm.12644
BibTeX
@article{Purja2024,
author = {Purja, Sujata and Kim, Minji and Elghanam, Yomna and Shim, Hae Jung and Kim, Eunyoung},
title = {Efficacy and safety of vancomycin compared with those of alternative treatments for methicillin‐resistant Staphylococcus aureus infections: An umbrella review},
journal = {Journal of Evidence-Based Medicine},
year = {2024},
volume = {17},
number = {4},
pages = {729--739},
doi = {10.1111/jebm.12644}
}
EUVIMED